Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (241-250 of 261) with videos related to

Pageof 27
Sort By:
Nature Medicine|June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsTimothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Iscience|February 24, 2023
Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancerDeanna Glassman, Mark S Kim, Meredith Spradlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid MalignanciesAparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
Cancer Discovery|March 26, 2026
Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid TumorsBurak Uzunparmak, Fei Su, Amber Johnson, et al.
Cancer Cell|June 12, 2019
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining EfficacyYong Fang, Daniel J McGrail, Chaoyang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor ActivityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Cancer Discovery|June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
The Oncologist|March 14, 2026
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and EquityCarlos Torrado, Clark R Andersen, Lei Kang, et al.
Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.
Pageof 27

Showing results (241-250 of 261) with videos related to

Sort By:
Pageof 27
Nature Medicine|June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsTimothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Iscience|February 24, 2023
Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancerDeanna Glassman, Mark S Kim, Meredith Spradlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid MalignanciesAparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
Cancer Discovery|March 26, 2026
Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid TumorsBurak Uzunparmak, Fei Su, Amber Johnson, et al.
Cancer Cell|June 12, 2019
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining EfficacyYong Fang, Daniel J McGrail, Chaoyang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor ActivityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Cancer Discovery|June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
The Oncologist|March 14, 2026
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and EquityCarlos Torrado, Clark R Andersen, Lei Kang, et al.
Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.
Pageof 27